Company news

Argenica Therapeutics Ltd news in 2025

Argenica Therapeutics Ltd's news releases, calls and decks from 2025, newest first.

View company

AI Analysis Reveals Efficacy In Severe Stroke Patients

December 10, 2025

Positive TNK Study Results Fulfil Key FDA Requirement

December 3, 2025

ARG-007 Efficacious Dose Validated in New Preclinical Study

November 24, 2025

Phase 2 Trial Promising Improvements in Functional Outcomes

October 14, 2025

Topline Phase 2 Trial Results of ARG-007 in AIS Patients

September 2, 2025

Trading Halt

August 31, 2025

Appendix 4E & Annual Report to 30 June 2025

August 28, 2025

Argenica Receives IND Feedback From FDA

August 13, 2025

Argenica Awarded Federal Government Funding

June 20, 2025

Argenica to Progress Clinical Development in TBI

June 17, 2025

Update on Investigational New Drug Application

June 9, 2025

New US Patent for Surgical Stroke

May 21, 2025

Last Patient Dosed in Phase 2 Stroke Trial

April 10, 2025

Updated - Main TBI Injury Study Annoucement

February 3, 2025

ARG-007 Shows Significant Neuroprotection in Main TBI Study

February 3, 2025

Positive DSMB Safety Outcome & Phase 2 Trial Progress Update

January 29, 2025

Decks in 2025